Literature DB >> 25185943

APOC3, coronary disease, and complexities of Mendelian randomization.

Jonathan C Cohen1, Stefan Stender2, Helen H Hobbs3.   

Abstract

Two new studies report that triglyceride (TG)-lowering mutations in APOC3 reduce coronary heart disease (CHD) (Crosby et al., 2014; Jørgensen et al., 2014). Here, we explore limitations of using Mendelian randomization to evaluate CHD risk, including potential confounding by the widespread use of statin therapy.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25185943      PMCID： PMC4235518          DOI： 10.1016/j.cmet.2014.08.007

Source DB:  PubMed          Journal:  Cell Metab        ISSN： 1550-4131            Impact factor:   27.287


  9 in total

1.  Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease.

Authors:  Ruth Frikke-Schmidt; Børge G Nordestgaard; Maria C A Stene; Amar A Sethi; Alan T Remaley; Peter Schnohr; Peer Grande; Anne Tybjaerg-Hansen
Journal:  JAMA       Date:  2008-06-04       Impact factor: 56.272

2.  Apolipoprotein CIII: 42 years old and even more interesting.

Authors:  Henry N Ginsberg; W Virgil Brown
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-03       Impact factor: 8.311

3.  Apolipoprotein E isoforms, serum cholesterol, and cancer.

Authors:  M B Katan
Journal:  Lancet       Date:  1986-03-01       Impact factor: 79.321

4.  A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.

Authors:  Toni I Pollin; Coleen M Damcott; Haiqing Shen; Sandra H Ott; John Shelton; Richard B Horenstein; Wendy Post; John C McLenithan; Lawrence F Bielak; Patricia A Peyser; Braxton D Mitchell; Michael Miller; Jeffrey R O'Connell; Alan R Shuldiner
Journal:  Science       Date:  2008-12-12       Impact factor: 47.728

5.  Major lipids, apolipoproteins, and risk of vascular disease.

Authors:  Emanuele Di Angelantonio; Nadeem Sarwar; Philip Perry; Stephen Kaptoge; Kausik K Ray; Alexander Thompson; Angela M Wood; Sarah Lewington; Naveed Sattar; Chris J Packard; Rory Collins; Simon G Thompson; John Danesh
Journal:  JAMA       Date:  2009-11-11       Impact factor: 56.272

6.  Loss-of-function mutations in APOC3, triglycerides, and coronary disease.

Authors:  Jacy Crosby; Gina M Peloso; Paul L Auer; David R Crosslin; Nathan O Stitziel; Leslie A Lange; Yingchang Lu; Zheng-zheng Tang; He Zhang; George Hindy; Nicholas Masca; Kathleen Stirrups; Stavroula Kanoni; Ron Do; Goo Jun; Youna Hu; Hyun Min Kang; Chenyi Xue; Anuj Goel; Martin Farrall; Stefano Duga; Pier Angelica Merlini; Rosanna Asselta; Domenico Girelli; Oliviero Olivieri; Nicola Martinelli; Wu Yin; Dermot Reilly; Elizabeth Speliotes; Caroline S Fox; Kristian Hveem; Oddgeir L Holmen; Majid Nikpay; Deborah N Farlow; Themistocles L Assimes; Nora Franceschini; Jennifer Robinson; Kari E North; Lisa W Martin; Mark DePristo; Namrata Gupta; Stefan A Escher; Jan-Håkan Jansson; Natalie Van Zuydam; Colin N A Palmer; Nicholas Wareham; Werner Koch; Thomas Meitinger; Annette Peters; Wolfgang Lieb; Raimund Erbel; Inke R Konig; Jochen Kruppa; Franziska Degenhardt; Omri Gottesman; Erwin P Bottinger; Christopher J O'Donnell; Bruce M Psaty; Christie M Ballantyne; Goncalo Abecasis; Jose M Ordovas; Olle Melander; Hugh Watkins; Marju Orho-Melander; Diego Ardissino; Ruth J F Loos; Ruth McPherson; Cristen J Willer; Jeanette Erdmann; Alistair S Hall; Nilesh J Samani; Panos Deloukas; Heribert Schunkert; James G Wilson; Charles Kooperberg; Stephen S Rich; Russell P Tracy; Dan-Yu Lin; David Altshuler; Stacey Gabriel; Deborah A Nickerson; Gail P Jarvik; L Adrienne Cupples; Alex P Reiner; Eric Boerwinkle; Sekar Kathiresan
Journal:  N Engl J Med       Date:  2014-06-18       Impact factor: 91.245

7.  Loss-of-function mutations in APOC3 and risk of ischemic vascular disease.

Authors:  Anders Berg Jørgensen; Ruth Frikke-Schmidt; Børge G Nordestgaard; Anne Tybjærg-Hansen
Journal:  N Engl J Med       Date:  2014-06-18       Impact factor: 91.245

8.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study.

Authors:  Benjamin F Voight; Gina M Peloso; Marju Orho-Melander; Ruth Frikke-Schmidt; Maja Barbalic; Majken K Jensen; George Hindy; Hilma Hólm; Eric L Ding; Toby Johnson; Heribert Schunkert; Nilesh J Samani; Robert Clarke; Jemma C Hopewell; John F Thompson; Mingyao Li; Gudmar Thorleifsson; Christopher Newton-Cheh; Kiran Musunuru; James P Pirruccello; Danish Saleheen; Li Chen; Alexandre F R Stewart; Arne Schillert; Unnur Thorsteinsdottir; Gudmundur Thorgeirsson; Sonia Anand; James C Engert; Thomas Morgan; John Spertus; Monika Stoll; Klaus Berger; Nicola Martinelli; Domenico Girelli; Pascal P McKeown; Christopher C Patterson; Stephen E Epstein; Joseph Devaney; Mary-Susan Burnett; Vincent Mooser; Samuli Ripatti; Ida Surakka; Markku S Nieminen; Juha Sinisalo; Marja-Liisa Lokki; Markus Perola; Aki Havulinna; Ulf de Faire; Bruna Gigante; Erik Ingelsson; Tanja Zeller; Philipp Wild; Paul I W de Bakker; Olaf H Klungel; Anke-Hilse Maitland-van der Zee; Bas J M Peters; Anthonius de Boer; Diederick E Grobbee; Pieter W Kamphuisen; Vera H M Deneer; Clara C Elbers; N Charlotte Onland-Moret; Marten H Hofker; Cisca Wijmenga; W M Monique Verschuren; Jolanda M A Boer; Yvonne T van der Schouw; Asif Rasheed; Philippe Frossard; Serkalem Demissie; Cristen Willer; Ron Do; Jose M Ordovas; Gonçalo R Abecasis; Michael Boehnke; Karen L Mohlke; Mark J Daly; Candace Guiducci; Noël P Burtt; Aarti Surti; Elena Gonzalez; Shaun Purcell; Stacey Gabriel; Jaume Marrugat; John Peden; Jeanette Erdmann; Patrick Diemert; Christina Willenborg; Inke R König; Marcus Fischer; Christian Hengstenberg; Andreas Ziegler; Ian Buysschaert; Diether Lambrechts; Frans Van de Werf; Keith A Fox; Nour Eddine El Mokhtari; Diana Rubin; Jürgen Schrezenmeir; Stefan Schreiber; Arne Schäfer; John Danesh; Stefan Blankenberg; Robert Roberts; Ruth McPherson; Hugh Watkins; Alistair S Hall; Kim Overvad; Eric Rimm; Eric Boerwinkle; Anne Tybjaerg-Hansen; L Adrienne Cupples; Muredach P Reilly; Olle Melander; Pier M Mannucci; Diego Ardissino; David Siscovick; Roberto Elosua; Kari Stefansson; Christopher J O'Donnell; Veikko Salomaa; Daniel J Rader; Leena Peltonen; Stephen M Schwartz; David Altshuler; Sekar Kathiresan
Journal:  Lancet       Date:  2012-05-17       Impact factor: 79.321

9.  A rare functional cardioprotective APOC3 variant has risen in frequency in distinct population isolates.

Authors:  Ioanna Tachmazidou; George Dedoussis; Lorraine Southam; Aliki-Eleni Farmaki; Graham R S Ritchie; Dionysia K Xifara; Angela Matchan; Konstantinos Hatzikotoulas; Nigel W Rayner; Yuan Chen; Toni I Pollin; Jeffrey R O'Connell; Laura M Yerges-Armstrong; Chrysoula Kiagiadaki; Kalliope Panoutsopoulou; Jeremy Schwartzentruber; Loukas Moutsianas; Emmanouil Tsafantakis; Chris Tyler-Smith; Gil McVean; Yali Xue; Eleftheria Zeggini
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919
  9 in total
  12 in total

Review 1.  The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk.

Authors:  Pratik B Sandesara; Salim S Virani; Sergio Fazio; Michael D Shapiro
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

Review 2.  Leveraging human genetics to guide drug target discovery.

Authors:  Nathan O Stitziel; Sekar Kathiresan
Journal:  Trends Cardiovasc Med       Date:  2016-08-26       Impact factor: 6.677

3.  Apoc2 loss-of-function zebrafish mutant as a genetic model of hyperlipidemia.

Authors:  Chao Liu; Keith P Gates; Longhou Fang; Marcelo J Amar; Dina A Schneider; Honglian Geng; Wei Huang; Jungsu Kim; Jennifer Pattison; Jian Zhang; Joseph L Witztum; Alan T Remaley; P Duc Dong; Yury I Miller
Journal:  Dis Model Mech       Date:  2015-06-04       Impact factor: 5.758

4.  Rare non-coding variants are associated with plasma lipid traits in a founder population.

Authors:  Catherine Igartua; Sahar V Mozaffari; Dan L Nicolae; Carole Ober
Journal:  Sci Rep       Date:  2017-11-27       Impact factor: 4.379

Review 5.  Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia.

Authors:  L Renee Ruhaak; Arnoud van der Laarse; Christa M Cobbaert
Journal:  Ann Clin Biochem       Date:  2019-03-19       Impact factor: 2.057

6.  Metabolic characterisation of disturbances in the APOC3/triglyceride-rich lipoprotein pathway through sample-based recall by genotype.

Authors:  Laura J Corbin; David A Hughes; Andrew J Chetwynd; Amy E Taylor; Andrew D Southam; Andris Jankevics; Ralf J M Weber; Alix Groom; Warwick B Dunn; Nicholas J Timpson
Journal:  Metabolomics       Date:  2020-06-03       Impact factor: 4.290

7.  Inactivating mutations in NPC1L1 and protection from coronary heart disease.

Authors:  Nathan O Stitziel; Hong-Hee Won; Alanna C Morrison; Gina M Peloso; Ron Do; Leslie A Lange; Pierre Fontanillas; Namrata Gupta; Stefano Duga; Anuj Goel; Martin Farrall; Danish Saleheen; Paola Ferrario; Inke König; Rosanna Asselta; Piera A Merlini; Nicola Marziliano; Maria Francesca Notarangelo; Ursula Schick; Paul Auer; Themistocles L Assimes; Muredach Reilly; Robert Wilensky; Daniel J Rader; G Kees Hovingh; Thomas Meitinger; Thorsten Kessler; Adnan Kastrati; Karl-Ludwig Laugwitz; David Siscovick; Jerome I Rotter; Stanely L Hazen; Russell Tracy; Sharon Cresci; John Spertus; Rebecca Jackson; Stephen M Schwartz; Pradeep Natarajan; Jacy Crosby; Donna Muzny; Christie Ballantyne; Stephen S Rich; Christopher J O'Donnell; Goncalo Abecasis; Shamil Sunaev; Deborah A Nickerson; Julie E Buring; Paul M Ridker; Daniel I Chasman; Erin Austin; Iftikhar J Kullo; Peter E Weeke; Christian M Shaffer; Lisa A Bastarache; Joshua C Denny; Dan M Roden; Colin Palmer; Panos Deloukas; Dan-Yu Lin; Zheng-zheng Tang; Jeanette Erdmann; Heribert Schunkert; John Danesh; Jaume Marrugat; Roberto Elosua; Diego Ardissino; Ruth McPherson; Hugh Watkins; Alex P Reiner; James G Wilson; David Altshuler; Richard A Gibbs; Eric S Lander; Eric Boerwinkle; Stacey Gabriel; Sekar Kathiresan
Journal:  N Engl J Med       Date:  2014-11-12       Impact factor: 91.245

8.  Systematic cell-based phenotyping of missense alleles empowers rare variant association studies: a case for LDLR and myocardial infarction.

Authors:  Aenne S Thormaehlen; Christian Schuberth; Hong-Hee Won; Peter Blattmann; Brigitte Joggerst-Thomalla; Susanne Theiss; Rosanna Asselta; Stefano Duga; Pier Angelica Merlini; Diego Ardissino; Eric S Lander; Stacey Gabriel; Daniel J Rader; Gina M Peloso; Rainer Pepperkok; Sekar Kathiresan; Heiko Runz
Journal:  PLoS Genet       Date:  2015-02-03       Impact factor: 5.917

Review 9.  Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?

Authors:  Geesje M Dallinga-Thie; Jeffrey Kroon; Jan Borén; M John Chapman
Journal:  Curr Cardiol Rep       Date:  2016-07       Impact factor: 2.931

10.  An APOC3 3'UTR variant associated with plasma triglycerides levels and coronary heart disease by creating a functional miR-4271 binding site.

Authors:  Sen-Lin Hu; Guang-Lin Cui; Jin Huang; Jian-Gang Jiang; Dao-Wen Wang
Journal:  Sci Rep       Date:  2016-09-14       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.